Press Release

« Back
Printer Friendly Version View printer-friendly version
Class A User Licenses for Accuray Products Awarded to 16 Hospitals in China

SUNNYVALE, Calif., Feb. 17, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced that class A user licenses for Accuray products were awarded to 16 hospitals during February by the Chinese National Health and Family Planning Commission (NHFPC). TomoTherapy® System licenses were received by 12 hospitals and CyberKnife® System licenses were received by four hospitals. Of the 16 licenses just issued, Accuray believes that six licenses will allow orders already in backlog to be recognized as revenue in the near future and 10 licenses are expected to lead to new system orders entered into backlog in the coming months. In total, between 2013 and year to date 2015, the NHFPC has released 32 of its planned 60 licenses. 

"There is a significant unmet patient need in China for precision radiation therapy systems that can effectively treat cancer while maximizing patients' quality of life," said Joshua H. Levine, president and chief executive officer of Accuray. "We're encouraged by the NHFPC's vote of confidence in our company's precise innovative tumor treatments and our systems' ability to make a positive difference in the lives of Chinese cancer patients. Our TomoTherapy and CyberKnife Systems will enable clinicians to offer their patients radiation therapy options, tailored to each patient's needs, which precisely target the tumor while avoiding healthy tissue."

About the CyberKnife and TomoTherapy Systems

The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to Accuray's selling presence in China, new order growth, revenue growth, market success, patient access, clinical results, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in Accuray's report on Form 10-K, filed on August 29, 2014, the company's report on Form 10-Q, filed on November 7, 2014, the company's report on Form 10-Q, filed on February 6, 2015, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


To view the original version on PR Newswire, visit:

SOURCE Accuray Incorporated

Beth Kaplan, Accuray, +1 (408) 789-4426,; or Kirsten Fallon, MSLGROUP in Boston, +1 (781) 684-0770,; or For Investors Contact: Chris Dailey, Investor Relations, EVC Group, +1 646-445-4801,